Atlanta Zoo 2016
Home | About Jay Hochman -Pediatric Gastroenterology Blog | Archives
July 14, 2016 7:00 am
“The monoclonal antibody vedolizumab may reduce biliary inflammation in patients with primary sclerosing cholangitis and comorbid inflammatory bowel disease, according to early, open-label study findings reported at the meeting sponsored by the European Association for the Study of the Liver” –according to GIHepNews: Biliary inflammation reduced by IBD drug
“Vedolizumab given to 27 patients with primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD) resulted in a 50% reduction or normalization of serum alkaline phosphatase levels in 17 cases (63%).”
This was an open-label, proof-of-concept study involving 27 patients aged 25-30 years with PSC and comorbid IBD.
My take: This is interesting but needs a lot more study.
Atlanta Zoo 2016
Posted by gutsandgrowth
Categories: Hepatology
Tags: primary sclerosing cholangitis, Vedolizumab
Mobile Site | Full Site
Get a free blog at WordPress.com Theme: WordPress Mobile Edition by Alex King.
[…] Vedolizumab for Primary Sclerosing Cholangitis (with … – gutsandgrowth […]
By Primary Sclerosing Cholangitis 2016 | gutsandgrowth on October 25, 2016 at 7:00 am
[…] Vedolizumab for Primary Sclerosing Cholangitis (with … – gutsandgrowth […]
By Should We Care About Subclinical Primary Sclerosing Cholangitis with Inflammatory Bowel Disease? | gutsandgrowth on October 26, 2016 at 7:04 am
[…] Vedolizumab for Primary Sclerosing Cholangitis (with … – gutsandgrowth […]
By Liver Problems with Inflammatory Bowel Disease | gutsandgrowth on April 27, 2017 at 7:02 am
[…] Vedolizumab for PSC-IBD? […]
By Ursodeoxycholic Acid in Pediatric Primary Sclerosing Cholangitis | gutsandgrowth on June 21, 2019 at 7:08 am